The goal of this project is to provide a platform for non-hormonal male contraceptive drug development by discovering candidate gene targets that can reversibly inhibit the spermatogonia-to-meiosis stage of spermatogenesis. The genetic alterations that lead to meiotic entry inhibition will be established as possible gene targets for contraception development and will be selected for reversibility and off-target effects. With this project, we aim to facilitate new approaches towards development of effective, safe and affordable contraception and to promote gender equity in family planning by sharing the responsibility of contraception equally amongst sexes.

Summary prepared by Dr. Jelena Lujic and Yochabed Miliard